SCHEMBL1866832

SCHEMBL1866832

CN(c1ccc([N+](=O)[O-])cc1F)C1CCN(C(=O)O)CC1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.51
MAPT P10636 3/20 0.47
NPSR1 Q6W5P4 1/20 0.47
HTT P42858 3/20 0.42
LMNA P02545 3/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
SLC6A9 P48067 1/20 0.42
SLC6A5 Q9Y345 1/20 0.42
KDM4E B2RXH2 1/20 0.40
THRB P10828 1/20 0.39
HSD11B1 P28845 2/20 0.39
KMT2A Q03164 1/20 0.38
TP53 P04637 1/20 0.38
HPGD P15428 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
GAA P10253 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1866831 1.00 ALDH1A1 (0.51) ALDH1A1MAPTNPSR1HTTLMNA
SCHEMBL6760065 0.81 ALDH1A1 (0.47) ALDH1A1MAPTLMNASLC6A9SLC6A5
SCHEMBL6760068 0.81 ALDH1A1 (0.47) ALDH1A1MAPTLMNASLC6A9SLC6A5
SCHEMBL1864686 0.79 ALDH1A1 (0.50) ALDH1A1MAPTNPSR1LMNAKDM4E
SCHEMBL27178979 0.75 ALDH1A1 (0.46) ALDH1A1MAPTNPSR1HTTKDM4E
SCHEMBL6764208 0.75 ALDH1A1 (0.47) ALDH1A1MAPTNPSR1HTTLMNA
SCHEMBL6764207 0.75 ALDH1A1 (0.47) ALDH1A1MAPTNPSR1HTTLMNA
SCHEMBL17803366 0.74 RAB9A (0.44) ALDH1A1MAPTNPSR1HTTLMNA
SCHEMBL27178780 0.74 ALDH1A1 (0.46) ALDH1A1MAPTNPSR1HTTKDM4E
SCHEMBL12273828 0.74 KCNH2 (0.43) ALDH1A1NPSR1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9108939-B2 (1, 1, 1,3,3,3-hexafluoro-2 hydroxypropan-2-yl) phenyl derivative, pharmaceutical compositions thereof and their use for the treatment of atherosclerosis MERCK SHARP & DOHME B.V. (NL) 2015-08-18 US disclosed
EP-2493855-B1 (1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl derivatives, pharmaceutical compositions thereof and their use for the treatment of atherosclerosis MERCK SHARP & DOHME (NL) 2014-02-26 EP disclosed
US-20120238574-A1 (1, 1, 1,3,3,3 -HEXAFLUORO-2 HYDROXYPROPAN- 2 -YL) PHENYL DERIVATIVE, PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR USE FOR THE TREATMENT OF ATHEROSCLEROSIS N.V. ORGANON (NL) 2012-09-20 US disclosed
EP-2493855-A1 (1,1, 1,3, 3, 3-HEXAFLUORO-2-HYDROXYPROPAN-2-YL) PHENYL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR USE FOR THE TREATMENT OF ATHEROSCLEROSIS MSD Oss B.V. (NL) 2012-09-05 EP disclosed
WO-2011051282-A1 (1,1, 1,3, 3, 3-HEXAFLUORO-2-HYDROXYPROPAN-2-YL) PHENYL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR USE FOR THE TREATMENT OF ATHEROSCLEROSIS N.V. ORGANON (NL) 2011-05-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120238574-A1 (1, 1, 1,3,3,3 -HEXAFLUORO-2 HYDROXYPROPAN- 2 -YL) PHENYL DERIVATIVE, PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR USE FOR THE TREATMENT OF ATHEROSCLEROSIS TGFB1, FPR1, TGFB2 ALDH1A1 220/4885MAPT 2944/4885NPSR1 2064/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.